Effect of FEV1/FVC on prognosis of limited stage small cell lung cancer
LIANG Rui1, HUI Zengqian2, WANG Jialin1, YU Yong1, ZHANG Boxiang3
1.Department of Hepatobiliary Chest Surgery, Shaanxi Provincial Corps Hospital of Chinese People’s Armed Police Force, Xi’an 710054, China; 2. Department of Medical Affairs,Shaanxi Provincial Corps Hospital of Chinese People’s Armed Police Force, Xi’an 710054, China; 3. Department of Thoracic Surgery and Oncology, the Second Department of Thoracic Surgery, Cancer Center of the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
Abstract：Objective To explore the effect of FEV1/FVC on the prognosis of limited stage small cell lung cancer.Methods The clinical data on 109 patients with small cell lung cancer treated at the First Affiliated Hospital of Xi’an Jiaotong University and our hospital between January 2012 and March 2015 was analyzed retrospectively. All the patients were treated with EP regimen chemotherapy and radiotherapy. Lung function was measured before treatment. The patients were divided into the experimental group (FEV1/FVC<0.70) and control group (FEV1/FVC<0.70). The correlations of FEV1/FVC with clinical factors, survival time and the influencing factors were evaluated.Results FEV1/FVC was closely related to patient mortality (P=0.008), local progression of small cell lung cancer (P=0.018) and distant metastasis (P=0.025). FEV1 (%) was related to patient mortality. Univariate analysis showed that chemotherapy cycles, FEV1% and FEV1/FVC had significant effect on the overall survival of patients with limited stage small cell lung cancer (P<0.05). Multivariate analysis showed that FEV1/FVC was an independent factor that influenced the overall survival of patients with limited stage small cell lung cancer. Age, chemotherapy cycle, FEV1% and FEV1/FVC had significant effect on progression-free survival of limited stage small cell lung cancer patients(P<0.05). Multivariate analysis showed that chemotherapy cycle and FEV1/FVC were independent factors influencing the progression-free survival of patients with limited-stage small cell lung cancer (P<0.05). The total survival time of the experimental group (FEV1/FVC<0.70) was significantly shortened, and the difference between the two groups was statistically significant (χ2=5.429, P<0.05).Conclusions FEV1/FVC may be a good prognostic indicator for limited stage small cell lung cancer before treatment.
George J, Lim J S, Jang S J, et al. Comprehensive genomic profiles of small cell lung cancer[J]. Nature, 2015, 524(7563): 47.
[2]
Durham A L, Adcock I M. The relationship between COPD and lung cancer[J]. Lung Cancer, 2015, 90(2): 121-127.
[3]
Zaynagetdinov R, Sherrill T P, Gleaves L A, et al. Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs[J]. Oncotarget, 2016, 7(5): 5470.
[4]
Griffin J P, Tolley E A, Zaman M K, et al. Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis[J]. J Cancer Res Ther, 2016, 4(1): 1-6.
[5]
Omote N, Hashimoto N, Morise M, et al. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3541.
Puig-Vilanova E, Rodriguez D A, Lloreta J, et al. Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer[J]. Free Radic Biol Med, 2015, 79: 91-108.
[8]
Putila J, Guo N L. Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer[J]. PLoS One, 2014, 9(6): e100994.
[9]
Bozinovski S, Vlahos R, Anthony D, et al. COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link[J]. Br J Pharmacol, 2016, 173(4): 635-648.
[10]
Gu X B, Tian T, Tian X J, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis[J]. Sci Rep, 2015, 5: 12493.
[11]
Gardner L D, Loffredo C A, Langenberg P, et al. Associations between history of chronic lung disease and non-small cell lung carcinoma in maryland: variations by sex and race[J]. Ann Epidemiol, 2018, 153(6):1326-1335.
[12]
Matsumoto Y, Ohara S, Furukawa R, et al. The prognosis of small cell lung cancer in patients with pulmonary fibrosis[J]. Anticancer Res, 2017, 37(10): 5791-5795.
[13]
Omote N, Hashimoto N, Morise M, et al. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12:3541-3547.
2019, Vol. 30 
